Masucci G, Wersäll P, Nielsen J, Nielsen H K, Wigzell H, Mellstedt H
Department of Oncology, Radiumhemmet, Karolinska Hospital, Stockholm, Sweden.
Hybridoma. 1989 Oct;8(5):507-16. doi: 10.1089/hyb.1989.8.507.
Peripheral blood lymphocytes (PBL) stimulated by interleukin-2 (IL-2) for 48-96h, generated killer cells against the human colon cancer cell line SW948. The killing capacity increased significantly when the specific mouse monoclonal antibody (MAb) 17-1A was present during the lytic process. The chimeric antibody 17-1A determined a significantly stronger cytotoxicity compared to mouse MAb 17-1A. MAb BR55-2 which recognizes a different antigen on SW948 target cells mediated a similar cytotoxicity as MAb 17-1A. Presence of alpha-interferon (IFN) during the lytic assay significantly enhanced the killing of the tumor by lymphokine activated killer (LAK) cells as well as by LAK cells and mouse MAb 17-1A. However, when chimeric MAb 17-1A and LAK cells were used alpha-IFN failed to increase the lytic activity, probably due to already maximum lysis in the system. Combinations of various biological response modifiers such as monoclonal antibodies, IL-2/LAK cells and alpha-IFN carry great promise to improve this kind of therapy for cancer patients.
外周血淋巴细胞（PBL）在白细胞介素-2（IL-2）刺激下培养48 - 96小时后，可产生针对人结肠癌细胞系SW948的杀伤细胞。在裂解过程中存在特异性小鼠单克隆抗体（MAb）17-1A时，杀伤能力显著增强。与小鼠MAb 17-1A相比，嵌合抗体17-1A具有显著更强的细胞毒性。识别SW948靶细胞上不同抗原的MAb BR55-2介导的细胞毒性与MAb 17-1A相似。在裂解试验中，α-干扰素（IFN）的存在显著增强了淋巴因子激活的杀伤细胞（LAK）以及LAK细胞和小鼠MAb 17-1A对肿瘤的杀伤作用。然而，当使用嵌合MAb 17-1A和LAK细胞时，α-干扰素未能增加裂解活性，这可能是由于系统中已达到最大裂解程度。各种生物反应调节剂如单克隆抗体、IL-2/LAK细胞和α-干扰素的联合应用有望极大地改善对癌症患者的此类治疗。
